JP2013523784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523784A5 JP2013523784A5 JP2013502966A JP2013502966A JP2013523784A5 JP 2013523784 A5 JP2013523784 A5 JP 2013523784A5 JP 2013502966 A JP2013502966 A JP 2013502966A JP 2013502966 A JP2013502966 A JP 2013502966A JP 2013523784 A5 JP2013523784 A5 JP 2013523784A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- pharmaceutically acceptable
- compound
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims description 6
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims description 6
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 206010039491 Sarcoma Diseases 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000032383 Soft tissue cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 206010024627 liposarcoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- -1 methoxy, methyl Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010073135 Dedifferentiated liposarcoma Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000000527 Germinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004718 centriole Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32132910P | 2010-04-06 | 2010-04-06 | |
| US32133210P | 2010-04-06 | 2010-04-06 | |
| US61/321,329 | 2010-04-06 | ||
| CAPCT/CA2010/000518 | 2010-04-06 | ||
| US61/321,332 | 2010-04-06 | ||
| PCT/CA2010/000518 WO2010115279A1 (en) | 2009-04-06 | 2010-04-06 | Kinase inhibitors and method of treating cancer with same |
| PCT/CA2011/000386 WO2011123946A1 (en) | 2010-04-06 | 2011-04-06 | Kinase inhibitors and method of treating cancer with same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523784A JP2013523784A (ja) | 2013-06-17 |
| JP2013523784A5 true JP2013523784A5 (enExample) | 2013-07-25 |
| JP5442906B2 JP5442906B2 (ja) | 2014-03-19 |
Family
ID=44761967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502966A Active JP5442906B2 (ja) | 2010-04-06 | 2011-04-06 | キナーゼインヒビターおよびこれを用いた癌の治療方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US8263596B2 (enExample) |
| EP (2) | EP2556070B1 (enExample) |
| JP (1) | JP5442906B2 (enExample) |
| KR (1) | KR101782668B1 (enExample) |
| CN (1) | CN102892766B (enExample) |
| AU (1) | AU2011238384B2 (enExample) |
| BR (1) | BR112012025496B1 (enExample) |
| CY (1) | CY1118610T1 (enExample) |
| DK (1) | DK2556071T3 (enExample) |
| EA (1) | EA023173B1 (enExample) |
| ES (2) | ES2603613T3 (enExample) |
| HR (1) | HRP20161498T1 (enExample) |
| HU (1) | HUE030651T2 (enExample) |
| IL (1) | IL221556A (enExample) |
| LT (1) | LT2556071T (enExample) |
| ME (1) | ME02545B (enExample) |
| MX (1) | MX2012011516A (enExample) |
| NZ (1) | NZ602350A (enExample) |
| PL (1) | PL2556071T3 (enExample) |
| PT (1) | PT2556071T (enExample) |
| SG (1) | SG183875A1 (enExample) |
| SI (1) | SI2556071T1 (enExample) |
| SM (1) | SMT201600430B (enExample) |
| TW (1) | TWI516262B (enExample) |
| WO (2) | WO2011123946A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2235004A4 (en) * | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| HRP20161498T1 (hr) | 2010-04-06 | 2016-12-16 | University Health Network | Inhibitori kinaza i njihova upotreba u liječenju raka |
| WO2012000103A1 (en) | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| ES2712717T3 (es) * | 2012-07-27 | 2019-05-14 | Sato Pharma | Compuesto de difluorometileno |
| ME03377B (me) | 2013-10-18 | 2020-01-20 | Univ Health Network | Sol i kristalni oblici inhibitora plk-4 |
| SG11201602882VA (en) * | 2013-10-18 | 2016-05-30 | Univ Health Network | Treatment for pancreatic cancer |
| CN104130175A (zh) * | 2014-06-13 | 2014-11-05 | 天津科技大学 | 不同位置取代吲哚酮类衍生物及其应用 |
| CN110072865B (zh) | 2017-02-08 | 2022-02-11 | 中国医药研究开发中心有限公司 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
| CN108947961B (zh) * | 2017-05-18 | 2021-06-04 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
| CN111225670A (zh) * | 2017-09-08 | 2020-06-02 | 大学健康网络 | 抑制Polo样激酶4的组合疗法 |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| MX2021012993A (es) | 2019-04-24 | 2021-12-10 | Univ Health Network | Forma cristalina s4 del inhibidor de plk4 fumarato de (1r,s2)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)- 1 h-imidazol-6-il)-5'-metoxispiro[ciclopropan-1,3'-indolin]-2'-ona. |
| KR20220124177A (ko) * | 2019-12-06 | 2022-09-13 | 유니버시티 헬스 네트워크 | 급성 골수성 백혈병 또는 골수형성이상증후군의 치료방법 |
| BR112022022409A2 (pt) | 2020-05-06 | 2023-02-07 | Ajax Therapeutics Inc | 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2 |
| CN112250614B (zh) * | 2020-10-20 | 2022-02-01 | 苏州大学 | 3-螺三元环吲哚酮衍生物的合成方法 |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| TW202300485A (zh) * | 2021-03-02 | 2023-01-01 | 大陸商上海齊魯製藥研究中心有限公司 | Plk4抑制劑及其用途 |
| AU2022272184A1 (en) | 2021-05-11 | 2023-11-30 | Oric Pharmaceuticals, Inc. | Polo like kinase 4 inhibitors |
| CN115677682B (zh) * | 2021-07-30 | 2023-07-18 | 上海齐鲁制药研究中心有限公司 | 螺环类plk4抑制剂及其用途 |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| WO2024006379A1 (en) * | 2022-06-30 | 2024-01-04 | Axonis Therapeutics, Inc. | Methods and compounds for inhibiting mkk7 enzymes |
| CN121039104A (zh) | 2023-04-06 | 2025-11-28 | 辉瑞大药厂 | 被取代的吲唑丙酸衍生化合物及其作为ampk活化剂的用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US5182397A (en) * | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
| GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1998007695A1 (en) | 1996-08-23 | 1998-02-26 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| JP2002522452A (ja) | 1998-08-04 | 2002-07-23 | スージェン・インコーポレーテッド | 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン |
| AU3770000A (en) | 1999-03-24 | 2000-10-09 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| EP1294688A2 (en) | 2000-06-02 | 2003-03-26 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| JP4414881B2 (ja) * | 2002-05-31 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾール化合物およびこれを含んでなる医薬組成物 |
| US7148249B2 (en) | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
| AU2003286604A1 (en) | 2002-10-21 | 2004-05-13 | Irm Llc | Oxindoles with anti-hiv activity |
| EP1696906A1 (en) | 2003-12-16 | 2006-09-06 | Leo Pharma A/S | Novel therapeutic use of indolinone derivatives |
| US20050211590A1 (en) | 2004-03-26 | 2005-09-29 | Mcclure George K | Protective cover for medical devices |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7309787B2 (en) * | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US20070135509A1 (en) | 2005-12-09 | 2007-06-14 | Blackburn Thomas P | Indolone compounds useful to treat cognitive impairment |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| WO2007109026A2 (en) | 2006-03-15 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Pten compositions and methods for detecting breast cancer |
| GB0606234D0 (en) | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| CA2690567A1 (en) | 2007-06-12 | 2008-12-18 | Boehringer Ingelheim International Gmbh | 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases |
| US20110201818A1 (en) | 2007-09-25 | 2011-08-18 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| CA2706075A1 (en) | 2007-11-20 | 2009-05-28 | University Health Network | Cancer diagnostic and therapeutic methods that target plk4/sak |
| JP2009173629A (ja) * | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| EP2235004A4 (en) * | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| WO2009111868A1 (en) * | 2008-03-11 | 2009-09-17 | University Health Network | Method of treating cancer using a neuropeptide y 5r (np y5r) antagonist |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| CA2728225A1 (en) | 2008-06-16 | 2010-01-21 | Tigris Pharmaceuticals, Inc. | Methods for determining sensitivity to aminoflavones |
| DE102008040187A1 (de) * | 2008-07-04 | 2010-01-07 | Robert Bosch Gmbh | Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung |
| US8455477B2 (en) | 2008-08-05 | 2013-06-04 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| JP5056876B2 (ja) | 2010-03-19 | 2012-10-24 | Ｊｆｅスチール株式会社 | 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法 |
| HRP20161498T1 (hr) | 2010-04-06 | 2016-12-16 | University Health Network | Inhibitori kinaza i njihova upotreba u liječenju raka |
| WO2012000103A1 (en) * | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| EA024026B1 (ru) | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| GB201109966D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating pten mutated or deficient cancer |
| US20140051679A1 (en) | 2011-10-12 | 2014-02-20 | Univeristy Health Networks | Kinase inhibitors and method of treating cancer with same |
| ME03377B (me) | 2013-10-18 | 2020-01-20 | Univ Health Network | Sol i kristalni oblici inhibitora plk-4 |
| SG11201602882VA (en) | 2013-10-18 | 2016-05-30 | Univ Health Network | Treatment for pancreatic cancer |
-
2011
- 2011-04-06 HR HRP20161498TT patent/HRP20161498T1/hr unknown
- 2011-04-06 BR BR112012025496-0A patent/BR112012025496B1/pt active IP Right Grant
- 2011-04-06 KR KR1020127029064A patent/KR101782668B1/ko active Active
- 2011-04-06 WO PCT/CA2011/000386 patent/WO2011123946A1/en not_active Ceased
- 2011-04-06 LT LTEP11764988.9T patent/LT2556071T/lt unknown
- 2011-04-06 CN CN201180018148.2A patent/CN102892766B/zh active Active
- 2011-04-06 EP EP11764989.7A patent/EP2556070B1/en active Active
- 2011-04-06 SI SI201131015A patent/SI2556071T1/sl unknown
- 2011-04-06 DK DK11764988.9T patent/DK2556071T3/en active
- 2011-04-06 ES ES11764988.9T patent/ES2603613T3/es active Active
- 2011-04-06 US US13/081,254 patent/US8263596B2/en active Active
- 2011-04-06 EP EP11764988.9A patent/EP2556071B1/en active Active
- 2011-04-06 NZ NZ602350A patent/NZ602350A/en unknown
- 2011-04-06 EA EA201270752A patent/EA023173B1/ru unknown
- 2011-04-06 ME MEP-2016-265A patent/ME02545B/me unknown
- 2011-04-06 WO PCT/CA2011/000387 patent/WO2011123947A1/en not_active Ceased
- 2011-04-06 ES ES11764989T patent/ES2639757T3/es active Active
- 2011-04-06 PT PT117649889T patent/PT2556071T/pt unknown
- 2011-04-06 HU HUE11764988A patent/HUE030651T2/en unknown
- 2011-04-06 SG SG2012065090A patent/SG183875A1/en unknown
- 2011-04-06 TW TW100111767A patent/TWI516262B/zh active
- 2011-04-06 JP JP2013502966A patent/JP5442906B2/ja active Active
- 2011-04-06 US US13/639,648 patent/US8921545B2/en active Active
- 2011-04-06 PL PL11764988T patent/PL2556071T3/pl unknown
- 2011-04-06 MX MX2012011516A patent/MX2012011516A/es active IP Right Grant
- 2011-04-06 AU AU2011238384A patent/AU2011238384B2/en active Active
-
2012
- 2012-06-21 US US13/529,542 patent/US8481533B2/en active Active
- 2012-08-21 IL IL221556A patent/IL221556A/en active IP Right Grant
-
2013
- 2013-07-03 US US13/935,021 patent/US9139563B2/en active Active
-
2014
- 2014-12-23 US US14/580,658 patent/US9579327B2/en active Active
-
2015
- 2015-08-11 US US14/823,057 patent/US9907800B2/en active Active
-
2016
- 2016-11-17 CY CY20161101184T patent/CY1118610T1/el unknown
- 2016-11-24 SM SM201600430T patent/SMT201600430B/it unknown
-
2017
- 2017-02-23 US US15/440,548 patent/US9796703B2/en active Active
- 2017-10-23 US US15/790,847 patent/US10077255B2/en active Active
-
2018
- 2018-02-22 US US15/902,143 patent/US10358436B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523784A5 (enExample) | ||
| JP7789016B2 (ja) | 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子 | |
| JP7013369B2 (ja) | Ｅｚｈ２阻害剤により卵巣の悪性ラブドイド腫瘍（ｍｒｔｏ）／高カルシウム血症型の卵巣の小細胞癌（ｓｃｃｏｈｔ）を処置するための方法 | |
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| US10583129B2 (en) | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer | |
| JP2015508103A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| JP2009541223A5 (enExample) | ||
| JP2010077141A5 (enExample) | ||
| JP2012506872A5 (enExample) | ||
| JP2016521280A5 (enExample) | ||
| KR20180042356A (ko) | 암 치료 방법 | |
| JP2018529742A (ja) | Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法 | |
| JP6014142B2 (ja) | Ｎ−ヒドロキシ−４−｛２−［３−（ｎ，ｎ−ジメチルアミノメチル）ベンゾフラン−２−イルカルボニルアミノ］エトキシ｝ベンズアミドの投与に関するスキーム | |
| JP2015510916A5 (enExample) | ||
| US11883423B2 (en) | Nucleobase analogue derivatives and their applications | |
| JP2013528215A5 (enExample) | ||
| JP2015534567A5 (enExample) | ||
| JP2013525455A5 (enExample) | ||
| EP3397254A1 (en) | Tryptamine-based ship inhibitors for the treatment of cancer | |
| TW200922595A (en) | Organic compounds | |
| FR3056108A1 (fr) | Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif | |
| JP2024508754A (ja) | 癌および前癌性パピローマウイルス病変を処置するための２－ｓリマンタジンおよび２－ｒリマンタジン |